Neurology News

Quality of life declined with use of certain enzyme-blocking drugs when measured against dopamine agonists in patients with Parkinson’s disease prescribed levodopa to correct motor issues, according to a study published in JAMA Neurology.

Healio has produced more than 4,000 articles related to COVID-19 since January 2020, a number that continues to grow, according to a press release from The Wyanoke Group.

Australian, American, Canadian and British panels that developed clinical practice recommendations most often consisted of white men and excluded historically underrepresented women, researchers reported in The Lancet.

Clinical-stage biopharmaceutical company Immunovant Inc. announced it has reached agreement with the FDA to initiate a phase 3 study of batoclimab in patients with myasthenia gravis in the first half of the year.

Although the rate of self-reporting was low, patients with posttraumatic epilepsy within 1 year of a traumatic brain injury sustained negative functional outcomes, according to a cohort study published in JAMA Network Open.

A new study on Choosing Wisely showed the campaign’s recommendations had strengths and opportunities for improvement, one of the study’s authors said.

Among patients with aneurysmal subarachnoid hemorrhage, those with recent cannabis use were more likely to have delayed cerebral ischemia than those without recent use, researchers reported.

The No Surprises Act, which officially took effect Jan. 1 as a way to protect patients from unexpected medical bills, already faces several lawsuits from health care organizations.

A validated tool was able to predict the inability to walk unaided at 4 and 26 weeks among patients with Guillain-Barré syndrome, according to study results published in Neurology.

The FDA granted orphan drug exclusivity for JZP258, an oral low-sodium oxybate solution for the treatment of idiopathic hypersomnia in adults, according to Jazz Pharmaceuticals.